Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01864538 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 study, sponsored by ImmunoGenesis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01864538: Clinical Trial Phase 2 study, sponsored by ImmunoGenesis.
NCT01864538 is a Phase 2 study that was terminated before completion, run by ImmunoGenesis. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01864538, a Phase 2 study, was terminated before completion, sponsored by ImmunoGenesis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
Interventions
- DRUG TH-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Why NCT01864538 stopped before completion
NCT01864538 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which TH-302 is the first listed.
NCT01864538 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01864538 about?
NCT01864538 is a clinical study titled "A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma". The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
What is the current status of trial NCT01864538?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2013-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01864538?
The interventions under investigation include: TH-302 (DRUG).
Who is sponsoring clinical trial NCT01864538?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01864538's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia